Brokers Issue Forecasts for Arvinas FY2026 Earnings

Arvinas, Inc. (NASDAQ:ARVN) – Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Arvinas in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings of ($1.84) per share for the year. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Thursday, May 1st. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. The firm’s revenue for the quarter was up 646.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.97) EPS.

A number of other equities analysts have also weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $14.00 price target (down from $24.00) on shares of Arvinas in a research report on Friday, May 2nd. Jefferies Financial Group restated a “hold” rating and set a $10.00 price target (down from $52.00) on shares of Arvinas in a research report on Friday, May 2nd. UBS Group reduced their target price on shares of Arvinas from $74.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. Guggenheim reduced their target price on shares of Arvinas from $32.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Finally, TD Cowen downgraded shares of Arvinas from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Arvinas presently has an average rating of “Moderate Buy” and a consensus target price of $20.29.

Arvinas Trading Down 1.3%

ARVN opened at $7.57 on Wednesday. The firm has a market capitalization of $552.54 million, a PE ratio of -2.73 and a beta of 2.19. Arvinas has a twelve month low of $5.90 and a twelve month high of $34.11. The firm’s 50-day moving average price is $7.36 and its 200 day moving average price is $13.67.

Institutional Investors Weigh In On Arvinas

Institutional investors have recently made changes to their positions in the stock. Affinity Asset Advisors LLC increased its position in shares of Arvinas by 180.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 630,000 shares of the company’s stock valued at $12,077,000 after acquiring an additional 405,000 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Arvinas in the fourth quarter valued at approximately $1,534,000. Kennedy Capital Management LLC grew its holdings in shares of Arvinas by 42.0% in the fourth quarter. Kennedy Capital Management LLC now owns 208,992 shares of the company’s stock valued at $4,006,000 after purchasing an additional 61,802 shares in the last quarter. BIT Capital GmbH grew its holdings in shares of Arvinas by 291.7% in the fourth quarter. BIT Capital GmbH now owns 263,527 shares of the company’s stock valued at $5,052,000 after purchasing an additional 196,246 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Arvinas by 7.2% in the fourth quarter. Northern Trust Corp now owns 631,131 shares of the company’s stock valued at $12,099,000 after purchasing an additional 42,638 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Arvinas

In other Arvinas news, insider Noah Berkowitz sold 8,658 shares of Arvinas stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the sale, the insider now directly owns 110,023 shares in the company, valued at $945,097.57. This trade represents a 7.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.73% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.